Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 436 results

      community PP405 Update and My Take on Pelage

      in Research/Science  86 upvotes 11 months ago
      Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

      community Scalp Massages /scalp hair oiling effective??

       5 upvotes 10 months ago
      The conversation discusses the effectiveness of natural remedies like scalp massages and oils for hair loss, with some users advocating for proven treatments like minoxidil and finasteride. The original poster prefers natural methods, while others argue that pharmaceuticals are more effective in combating hair loss.

      community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

       371 upvotes 8 months ago
      Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Brotzu lotion update

       87 upvotes 8 years ago
      A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.

    Learn

    6 / 801 results

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn KX-826

      • Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.